Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Maximizing Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

NCT06075524 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06075524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06075524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Maximizing Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Lead sponsor
Mayo Clinic
Phase
Observational
Overall status
Recruiting
Start date
June 15, 2015
Completion date
December 31, 2028
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iii cutaneous melanoma ajcc v8, clinical stage iv cutaneous melanoma ajcc v8, locally advanced lung carcinoma, locally advanced malignant solid neoplasm, locally advanced melanoma, metastatic lung carcinoma, metastatic malignant solid neoplasm, metastatic melanoma, stage iii lung cancer ajcc v8, stage iv lung cancer ajcc v8